host group investor meet franci desouza ilmn ceo earlier
week left discuss increment enthus ilmn outlook also
take opportun outlin thought outlook balanc
year look ahead updat model increas price
target
follow select key observ meet struck
right balanc acknowledg sequenc consum revenu growth
accept also maintain sincer enthusiasm regard ilmn growth outlook
build last point understand unwil set new long-term growth
target also clear assert understand sequenc consum
growth norm y/i past period growth slow
typic subsequ rebound respons question regard
whether guidanc set level reflect notion take lump
agre intent sinc seen uk biobank
fund ostens key caus miss still guidanc also note
miseq consum weak still appear transitori build
last point clear note guidanc polici move forward reflect
goal avoid repeat challeng especi popseq howev note
clear enthusiasm popseq share big revenu number base preliminari
analysi didnt hear lot increment seemingli believ
regulatori review go distanc detail provid page
ilmn share valu declin flat ytd subsequ
strength week good year linger question
combin meet deep dive model review lead
us conclud risk/reward attract current level note herein
page see littl risk expect believ posit guid
expect januari level consist current consensu
expect near term believ pois meet-or-modestli beat
consensu expect keep mind quarter still week go
still earli addit detail pleas see preview sheet page ye
question execut year pristin said scenario analysi
page suggest price target quit reason see bull case
like bear case note basi share trade price-to-earnings
turn norm
made modest chang forecast larg clean
made materi chang forecast discuss page believ
leav room upsid assumpt notabl still remain
consensu ep expect also modestli increas price
target consist updat dcf translat ep
forecast coupl clean quarter reason guidanc updat earli next
year like get stock level layer popseq bull case
becom less aspir continu page
pleas see page report import disclosur
well posit maintain leadership expand high end genet
tool research market drive robust growth nipt market increasingli displac
exist diagnost establish reimburs act arm dealer
elimin barrier sequenc becom increasingli use oncolog adjac
market believ factor continu translat robust doubl digit revenu
earn growth justifi premium valuat
nextseq key growth driver
continu evolv favor
nextseq placement continu increas
new instruments/kit surpris
sourc revenu
expand use sequenc increas
becom much favor
novaseq unabl catalyz
strength nextseq placement
concern build oper leverag
slow materi
hiseq bigger expect headwind
leader genet tool segment tool diagnost market
segment compani broad portfolio system consum analysi tool
design simplifi genet analysi address rang genom complex price
point throughput enabl research select best solut scientif
challeng market leader next gener sequenc increasingli focus
reproduct health includ nipt act arm dealer emerg oncolog
recent host group investor meet ceo franci desouza
discuss left us better understand challeng increas
confid abil meet financi target fortifi outlook
growth re-acceler level least consist consensu seri
select question address discuss
come year manag set guidanc sequenc consum revenu
growth subsequ miss financi target growth target
revenu categori cut manag indic much
attribut popul sequenc program come expect also
note benchtop sequenc assumpt reduc well
specif sequenc consum manag acknowledg transit
hiseq novaseq creat headwind estim declin hiseq
consum revenu point revenu headwind indic
tremend materi origin contempl guidanc gener
speak clinic research demand track expect sequenc
beyond sequenc consumer/dtc demand clearli much weaker
expect recogn manag expect growth
segment revenu miss due dtc
servic consum manag believ improv
point note continu model microarray servic larg dtc
year also estim microarray consum revenu driven
dtc expect materi declin revenu busi area
made abundantli clear growth rate remot
satisfi build note period growth
drop past period last long true
expect sustain growth rate segment also
acknowledg rate consist histor norm least
build note novaseq consum revenue/box continu
increas q/q top popseq challeng comparison
look ahead think return sequenc consum revenu
growth quit possibl via continu improv novaseq consum
util consist data sourc core lab survey link
steadi util rate nextseq miseq
popul sequenc popseq key focu area investor
one program larg capit
shortfal attribut popul initi take longer
expect ramp increment previous expect
popseq program larg remov revis guidanc
delay reduct popseq revenu clearli disappoint
manag indic continu see increas number program
rel begin year continu expect
program initi sequenc point uk announc
wednesday launch genome-decod research program uk
biobank link note program back fund
glaxosmithklin plc johnson johnson astrazeneca initi
sequenc analyz genet code volunt almost complet
plan next year believ program repres
popseq instrument revenu slip sinc
expect novaseq instrument revenu put good posit
manag also indic migrat genom england research
project implement within nh taken longer expect sign
continu point eventu adopt program could gener revenu
perpetu addit new administr call increas
genom fund secretari clear support genom initi
believ uk biobank nh develop lessen near term popseq
us manag continu expect us program begin
note delay program larg due regulatori protocol
relat sequenc cost
forecast pace program tough accordingli manag
expect continu conserv popseq assumpt includ
financi guidanc said note manag calcul total
potenti popseq sequenc consum revenu valu
sequenc consum forecast base public disclosur
popseq program frame opportun made clear number
get big remain enthus associ
clinic applic reproduct health oncolog genet diseas etc account
ilmn sequenc consum shipment segment grew
y/ manag expect end market continu higher
growth ilmn research busi
within nipt see opportun drive adopt compani believ
us nipt market penetr today drive self-pay custom
uptak continu larg percentag market averag risk
cover drive content evidenc ilmn expand veriseq
product launch note respons question lower cost nipt
specif ip-rel access fee possibl lower-cost competit
note continu work reduc nipt cost includ access fee
also note ip-rel fee part pool accordingli note
work pool particip
oncolog continu pursu strategi creat end end solut
enabl market provid specialti lab gh
infrastructur product need succeed
last month announc svp clinic genom would leav
compani earli busi would integr back overal
organ manag indic done clinic busi
matur enough longer requir incub integr ensur
everi part busi includ clinic focu
satisfi enthus on-going momentum clinic end market
especi variou new financ gh thrive etc
compani clinic rigor use technolog
action past month uk heighten uncertainti
regard likelihood success acquir
still work hard get deal finish line includ educ
offici sequenc market differ
technolog also get sens us ftc activ intensifi ftc
cogniz timelin set decis deadlin decemb
review goe beyond novemb need agre extend
deadlin deal complet
manag reiter work regul continu expect
deal close end year go distanc indic
plan convers discuss next step deal
complet novemb regard anti-trust approv note
lot compani uk decis goe howev
us decis goe possibl appeal would also note
context discuss program becam appar
long-read sequenc program develop longer term potenti
altern deal get approv said
sequenc tend lead sequenc organiz oper
sales/commerci synergi still render combin attract
compani gener impress growth via innov histori
mani investor ask innov sustain tough quarter
note key area focu continu drive sequenc cost
genom still goal compani use novaseq architectur
manag stress novaseq creat drive long-term instrument
upgrad cycl enabl innov chip launch
biggest histor invest drive platform improv
compani also focus launch addit end-to-end product veriseq
manag note compani also focus innov
priorit therefor de-emphasize certain area
commodit librari prep forens favor area believ better suit
new product develop
growth expect past quarter got clear
messag expect temporari past
anyth manag attempt better job direct invest
like area drive differenti growth open even
market edico acquisit invest shouldnt lost mix
like short-term slowdown novaseq gener sale quickli
platform develop
look well posit least meet beat consensu expect
see revenu upsid potenti see upsid potenti novaseq
instrument placement forecast servic forecast see limit risk
ep expect believ compani track least meet slightli
exceed financi target cut materi subsequ miss
clear rel lower bar expect addit neg catalyst
year end although continu believ deal complet
may
expect guid revenu growth someth
street current look growth get growth rate
nomin servic microarray growth lsd sequenc instrument growth
sequenc consum growth view achiev given recent
novaseq trend real pick nextseq miseq trend given increasingli
small headwind associ hiseq believ compani gener high-
teen ep growth scenario given manag
indic major catch requir spend post cut
back close expect meaning dilut ultim believ
scenario similar trend support upsid confid
driver upsid popseq materi stock upsid could materi
perform financi expect past quarter
result increas uncertainti regard compani inher multi-year
growth outlook current view comfort posit
gener low-to-mid teen revenu growth higher ep growth rate next
year believ achiev even without bull case popseq contribut
dcf support price target scenario translat
ep believ prove reason multipl next month
clinic consum and/or popseq program drive upsid believ share
could trade higher bull case next year bear case
requir prolong period growth limit leverag like
translat stock price
given ilmn uniqu posit leader genet tool inher expand
demand tool would buyer current level see
reason price target view potenti rang outcom posit bias
per share
confid build sustain mid-teens-plu revenu growth via
combin sustain high-teens-plu consum growth possibl
possibl key driver consum growth includ popseq clinic adopt
mean novaseq replac near term
servic also could sourc upsid rel model popseq
gross margin expans per year
oper leverag level exceed histor norm
forward multipl return norm appli cowen
ep estim roll forward
total instrument revenu flattish next year requir stabl
novaseq placements/year
consum revenu grow next year trail
averag driver includ list bull case
nomin growth microarray dtc servic
limit competit impact specif competit area
nipt
gross margin expans
oper margin move assum meaning
catch requir
dcf support current forward line top-tier growth comp
year forward mean price-to-earnings cowen ep estim
instrument revenu becom headwind current contempl
consum growth drop clinic slowdown seem
unlik especi given recent ipo popseq flow thru nipt altern
multipl ep estim
cowen compani thomson eikon
ep increas forecast account enhanc oper focu
revenu revenu reduct function reduc outlook miseq
annual consum revenu per box pend updat
subsequ weaker expect perform note previous could
prove conserv base manag commentari
ep cut ep forecast due larg miseq cut take slightli
conserv stanc outlook consum gross margin improv
given potenti larg popul program could discount
revenu reduc revenu due sequenc modestli cut
novaseq placement forecast probabl conserv cut novaseq
annual consum forecast probabl low given trend
increas hiseq headwind assumpt materi cut nextseq
miseq unit placement forecast level pretti flat like
notabl assumpt still lead us sequenc consum revenu
growth
continu forecast microarray revenu declin could low
consumer/dtc rebound keep mind favor comparison continu
forecast decreas servic revenu sale account consum
pressur also could low given comp posit instrument service/clin
nipt trend possibl popseq upsid
ep cut ep forecast larg function revenu
reduct reduc gross margin forecast account possibl popseq
discount note still consensu see potenti
cowen compani compani report
cowen vs consensu mm except revenu guid y/i y/i expect declin y/i q/qoper opex q/q sale opex y/i ep includ helix dilutionselect revenu metric mm except metricstot could mm upsid believ place novaseq spite delay relat popgen program ostens uk biobank base septemb report uk biopbank program fund manag commentari believ placement occur addit core lab survey earlier year indic core demand novaseq translat placement come quarter accordingli believ forecast instrument q/q placement declin could prove conserv sequenc statement mm except growth could low expect sourc leverag consist overal opex guidanc per upsid model could moregrowth count could high could even leverag given hold back incent comp would off-set low consensu note line guidanc gross margin like declin q/q consist manag commentari pleas note right upsid potenti like would result lower gross margin think could possibl instrument could drive upsid think could possibl discuss believ could low due novaseq comfort forecast could slight upward bia via novaseq miseq think could possibl forecast microarray servic declin y/i q/q declin microarray servic larg consum ancestri com usual lower vs season said comparison favor last quarter sequenc servic instrument servic grow least modestli y/i could upsid follow key placement assumpt novaseq q/q note could conserv hiseq think placement nextseq q/q could high would repres risk like off-set potenti novaseq upsid miseq flat past quarter comfort forecast follow key annual consum pull thru assumpt q/q core lab survey target hiseq q/q y/i notabl total retir headwind total revenu nextseq middl guidanc rang miseq low end rang q/q improv comfort forecast forecast microarray instrument revenu flat consist recent quarter consum flat past quarter y/i given on-going headwind consum genet believ assumpt reason pleas note estim microarray consum link consum accordingli essenti forecast declin y/i note reason materi decreas difficult instrument comparison comfort current consensu expect upsid potenti believ novaseq forecast placement q/q could prove conserv given core-lab survey recent uk biobank news addit believ servic forecast could prove conserv ultim think total sequenc revenu could grow y/i key driver upsid rel forecast like novaseq placement potenti partial nextseq off-set potenti sequenc consum upsid would like via novaseq mayb miseq rebound q/q
cowen compani compani report
thomson eikon cowen compani compani report
cowen compani compani report
yr cagrcomments/guidancetot revenu guid y/i y/yrevenu product classproduct inst servic incl nextbio revenu geographyamerica middl east growth y/i middl east revenu growth expect almost headwind salesproduct middl east sequenc guid y/i mid-teen growth revenu growth total total servic revenu guid slightli y/yservic revenu growth microarray guid y/i flat growth revenu growth total revenu growth wors anticip apr expect mid-teen y/i comment purchas instrument lh array system strength partial function scale lhcowen comment relat instrument maint contract remaind nipt popgen core ip/licens oncolog collabor cowen comment manag indic largerli consum littl mainten believ largerli ancestri com cowen
cowen compani compani report thomson eikon
mm except per share guidancenet revenu guid y/i y/yreport expect declin y/i q/q gener oper opex q/q sale opex y/i sale non-oper interest incom lower incom q/qearn line year slightli q/qnet loss attribut nci add helix dilut expect earn per ep includ helix dilutionshar gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit greater-than-expect reduct academ
govern research fund competit commerci avail potenti
disrupt technolog price pressur caus competit increas demand
lower-pr instrument run-tim cost neg regulatori dynam
